Jan 13 (Reuters) - Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
Dealmakers are anticipating a surge in megadeals worth over $10 billion, buoyed by hopes of a more lenient antitrust environment under the incoming Trump administration.
The following is a list of deals that took place on Monday ahead of the JPMorgan Healthcare Conference:
GSK-IDRx
British drugmaker GSK GSK.L said that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx.
J&J-Intra-Cellular Therapies
Johnson & Johnson JNJ.N said it will buy Intra-Cellular Therapies ITCI.O for $14.6 billion, with plans to fund the deal through a combination of cash and debt.
Eli Lilly-Scorpion Therapeutics
Eli Lilly LLY.N plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments.
AbbVie-Simcere Pharmaceutical
AbbVie ABBV.N has obtained the option to license a new blood cancer drug candidate from Simcere Pharmaceutical's 2096.HK unit for markets outside China, in a deal valued at up to $1.06 billion.
(Reporting by Kamal Choudhury and Puyaan Singh in Bengaluru; Editing by Shailesh Kuber)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。